Funding sources This study was funded in part by a grant from Epiderm, Australia. Epiderm played no role in study design, data collection, data analysis, interpretation of data, manuscript preparation or publication decisions.
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Version of Record online: 5 OCT 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 167, Issue 5, pages 1153–1160, November 2012
How to Cite
Anforth, R.M., Blumetti, T.C.M.P., Kefford, R.F., Sharma, R., Scolyer, R.A., Kossard, S., Long, G.V. and Fernandez-Peñas, P. (2012), Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. British Journal of Dermatology, 167: 1153–1160. doi: 10.1111/j.1365-2133.2012.11155.x
Conflicts of interest The following conflicts of interest are declared: R.F.K. with GlaxoSmithKline and Roche; R.A.S. with GlaxoSmithKline, Roche and Abbott Molecular; G.V.L. with GlaxoSmithKline; and P.F.-P. with Roche.
- Issue online: 29 OCT 2012
- Version of Record online: 5 OCT 2012
- Accepted manuscript online: 16 JUL 2012 08:18PM EST
- Accepted for publication 11 July 2012
Table S1. Human papillomavirus (HPV) immunofluorescence and p16 testing on 10 verrucal keratoses and six squamous cell carcinoma (SCC) tissue samples. Nuclear staining for HPV recorded as positive or negative. p16 staining intensity was graded as: 0, no staining; 1, weak staining, 2, moderate staining; and 3, strong staining.
|BJD_11155_sm_TableS1.doc||54K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.